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Circulating endothelial progenitor cells (EPCs) provide revascularisation for cardiovascular disease and the expansion of these cells
opens up the possibility of their use as a cell therapy. Herein we show that interleukin-3 (IL3) strongly expands a population of human
non-adherent endothelial forming cells (EXnaEFCs) with low immunogenicity as well as pro-angiogenic capabilities in vivo, making
their therapeutic utilisation a realistic option. Non-adherent CD133+ EFCs isolated from human umbilical cord blood and cultured
under different conditions weremaximally expanded by day 12 in the presence of IL3 at which time a 350-fold increase in cell number
was obtained. Cell surfacemarker phenotyping confirmed expression of the hematopoietic progenitor cell markers CD133, CD117 and
CD34, vascular cell markers VEGFR2 and CD31, dim expression of CD45 and absence of myeloid markers CD14 and CD11b. Functional
experiments revealed that EXnaEFCs exhibited classical properties of endothelial cells (ECs), namely binding ofUlex europaeus lectin,
up-take of acetylated-low density lipoprotein and contribution to EC tube formation in vitro. These EXnaEFCs demonstrated a
pro-angiogenic phenotype within two independent in vivo rodent models. Firstly, a Matrigel plug assay showed increased
vascularisation in mice. Secondly, a rat model of acute myocardial infarction demonstrated reduced heart damage as determined by
lower levels of serum creatinine and a modest increase in heart functionality. Taken together, these studies show IL3 as a potent
growth factor for human CD133+ cell expansionwith clear pro-angiogenic properties (in vitro and in vivo) and thusmay provide clinical
utility for humans in the future.
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Endothelial progenitor cells (EPCs) circulate in peripheral blood
and migrate to a site for vascular formation and repair (Asahara
et al., 1997). The pro-angiogenic nature of EPCs is of
therapeutic interest for a range ofmedical conditions, including
wound healing (Cho et al., 2003), limb and myocardial ischemia
(Eizawa et al., 2004; Laing et al., 2007; Schmidt-Lucke et al.,
2005; Werner et al., 2005) and diabetes (Loomans et al., 2004),
where low numbers of circulating EPCs have been linked to
disease. To overcome this problem, EPCs as a cell-based
therapy have been widely pursued and involves transplantation
of healthy and functional cells to replenish damaged cells and
repair injured tissue. Notably, pre-clinical and pilot clinical
studies have yielded poor results suggesting that treatmentwith
EPCs is yet to be fully realised and that significant modifications
are clearly required (reviewed in Sen et al., 2011).
Studies suggest that there are three different types of EPCs;
namely the adherent ‘early EPCs’(Hill et al., 2003; Hur et al.,
2004; Ito et al., 1999), the adherent ‘late outgrowth’ EPCs
(Ingram et al., 2004; Lin et al., 2000) and the ‘non-adherent
EPCs’ that we and others have recently characterised (Appleby
et al., 2012; Janic et al., 2010; O et al., 2011). While all three
populations demonstrate the capacity to improve neovascular-
isation in preclinical models, they differ with respect to their
capacity to differentiate into endothelial cells (ECs) and to
physically form new blood vessels in vivo. ‘Early EPCs’ are cells
with haematopoietic characteristics and share features with
immune cells, particularly CD14 expression of monocytes/
macrophages and are obtained from short-term cultures of
4–7 days in vitro (Hill et al., 2003; Hur et al., 2004; Ito et al.,
1999). Most studies suggest that these short-term cell
enrichment protocols enhance vessel formation by paracrine
assistance by providing a potent mixture of pro-angiogenic
growth factors rather than integration into the vasculature for
repair (reviewed in Sen et al., 2011). The ‘late outgrowth EPCs’
have been rebadged endothelial colony forming cells (ECFCs)
and are the EPC type most studied as they display spontaneous
vasculogenic properties, integrate long-term into the systemic
vasculature of the host animal and remodel into arteries and
veins in vivo (Bompais et al., 2004; Gulati et al., 2003; Hur et
al., 2004; Ingram et al., 2004; Melero-Martin et al., 2007;
Timmermans et al., 2007). ECFCs express the mature EC
marker CD144 (VE-cadherin), do not express the progenitor cell
marker CD133 and are phenotypically very similar to fully
differentiated ECs with the exception of an increased
proliferative rate (Hur et al., 2004; Timmermans et al.,
2007). ECFCs have entered the clinic with, for example,
2.5 × 106 autologous ECFCs per kilogramme (1.75 × 108 for a
70 kilogrammeadult) infused intravenously approximately four
weeks after BM aspiration and cell expansion. The same
number of cells is again transplanted approximately one week
later (NCT01468064, (Lee et al., 2010)). Importantly, the time
required to generate the ~2 × 108 of autologous ECFCs is
approximately 5 weeks which (i) falls well outside of the
effective cell delivery time of 4–10 days post-ischemic event
(Dimmeler et al., 2008) and (ii) attracts a high cost associated
with long term culture and expansion of adherent cells.
Clearly, if we are to provide EPCs as a cell based therapy new
strategies to improve their expansion are required and
investigation of an allogeneic source is warranted.In this study we demonstrate the effectiveness of
interleukin (IL)-3 to rapidly expand CD133+ non-adherent
endothelial forming cells (naEFCs) to a therapeutically
relevant number within a clinically beneficial time frame.
Recently we and others demonstrated that naEFCs are
capable of in vivo vascularisation (Appleby et al., 2012;
Janic et al., 2010) and herein we show the expansion of
freshly isolated or cryopreserved cells in a serum-freemedium
to N2 × 108 within only 12 days (EXnaEFCs). Furthermore, we
demonstrate that these cells harbour low immunogenicity
with validated pro-angiogenic capabilities in vitro and in vivo.
We also demonstrate improvement of heart function in a rat
model of acute myocardial infarction.Materials and methods
Ethics statement
The collection of primary human umbilical vein endothelial
cells (HUVECs) and umbilical cord blood was approved by the
Human Research Ethics Committees of the Royal Adelaide
Hospital and the Women's and Children's Health Network,
Adelaide, South Australia. Informed written consent was
obtained from the subjects in accordance with the ‘Declara-
tion of Helsinki’. Animal experiments were approved by the
Animal Ethics Committee of SA Pathology and conform to the
guidelines established by the ‘Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes’.Isolation and culture of CD133+ naEFCs
Umbilical cord blood was collected from healthy, consenting
women undergoing elective caesarean sections in cord blood
bags (MacroPharma, Mouvaux, France). Blood was diluted
1:1 in sterile phosphate buffered saline (PBS). Mononuclear
cells (MNCs) were isolated using Lymphoprep™ (Axis-Shield,
Oslo, Norway). Mononuclear cells were washed in human
umbilical vein endothelial (HUVE) media [Media 199
(Sigma-Aldrich, St. Louis, MO); containing 20% FCS (Hyclone,
Logan, UT), 1.5% sodium bicarbonate, 2% HEPES buffer
solution, penicillin streptomycin, sodium pyruvate (Gibco
Invitrogen, Gaithersburg, MD) and non-essential amino acids
(Sigma-Alrich)]. Cells were blocked with 10 ml of 5% normal
mouse serum (Abcam, Cambridge, England) in HUVEmedia for
10 min, washed in HUVE media and blocked with 100 μl of
human FcR blocking reagent (Miltenyi Biotec, Bergisch
Gladbach, Germany) prior to an incubation with 100 μl of
CD133+ microbeads (Miltenyi Biotec) for 30 min at 4 °C. Cells
were washed again in HUVE media and CD133+ cells isolated
using the AutoMacsPro (Miltenyi Biotec) as per manufacturer's
instructions. CD133+ cells were resuspended at a concentra-
tion of 0.5–1 × 106 cells/ml in CellGro SCGM (CellGenix
GmbH, Freiburg, Germany) supplemented with 10 ng/ml
Thrombopoietin (TPO, Sigma-Alrich), 40 ng/ml stem cell
factor (SCF) and 40 ng/ml Ftl3L (both R&D Systems, Minneap-
olis, MN), here on in referred to as CellGro medium. In some
experiments IL3 (20 ng/ml) and placental growth factor
(PlGF, 25 ng/ml, R&D Systems) were added to the media in
addition to the other growth factors.
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CD133+ isolated EXnaEFCs were suspended at 1 × 106 cells/ml
at 4 °C in cryopreservation media [90% FCS (Hyclone) and 10%
DSMO (Sigma-Alrich)] in a Cyto.S™ vial (Greiner Bio-One GmbH,
Frickenhausen, Germany) immediately following isolation and
placed in a Nalgene Mr. Frosty™ freezing container (Thermo
Fisher Scientific,Waltham,MA) for 24 h at −80 °C before being
transferred to liquid nitrogen. To thaw EXnaEFCs, the vial was
placed into a 37 °C water bath prior to cold HUVE media
(10 ml) being added dropwise. Cells were centrifuged at 300 ×g
for 5 min and pelleted cells were resuspended in CellGro
medium to 0.5 × 106 cells/ml. Every 2–3 days cells were
counted and viability was assessed using a 0.4% trypan blue
solution and haemocytometer. Additional media were then
added to maintain the cells at 0.5 × 106 cells/ml.
Human umbilical vein endothelial cell (HUVEC)
isolation and culture
Primary HUVECs were extracted from human umbilical veins
by collagenase digestion and cultured in HUVE media as
previously described (Litwin et al., 1997; Wall et al., 1978)
and were used after no more than two passages.
Flow cytometric analysis of cell surface protein
expression
EXnaEFCs were analysed for cell surface expression of
various markers by flow cytometry. Cells were treated with
10 μl Human FcR block (Miltenyi Biotec) diluted in 30 μl of
HUVE media. They were then incubated with a panel of
mouse anti-human fluorochrome-conjugated antibodies against
progenitormarkers CD34, CD117, and CD133, vascularmarkers
CD31, CD144, and CD146 and VEGFR2, hematopoietic markers
CD14, CD38, and CD45 and IL3RA or appropriate isotype
controls (all BD Bioscience, except anti-CD133 is Miltenyi
Biotec) for 30 min at 4 °C. Cells were washed in PBS and 7AAD
(BD Biosciences) was added prior to cell analysis on an Accuri
flow cytometer (BD Biosciences) to determine viability. Data
was analysed using FCS Express 4 Flow Cytometry: Research
Edition (De Novo Software, Los Angeles, CA).
Up-take of acetylated-low density lipoprotein and
U. europaeus lectin binding
Cells were incubated at 37 °C for 4 h with 10 μg/ml
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine per-
chlorate acetylated-low density lipoprotein (DiI-Ac-LDL;
Biomedical Technologies, Stoughton, MA, USA) and 10 μg/ml
of FITC bound U. europaeus agglutinin 1 lectin (UEA,
Sigma-Aldrich). Incorporation of DiI-Ac-LDL and binding of
FITC-UEA-1 was assessed using flow cytometry and compared
to unlabelled control cells.
Immunoblotting
Cells expanded for 10 days were starved of growth factors
for 5 h prior to stimulation without or with IL3 (50 ng/ml,
in house) for 10 min prior to being lysed in PLCLB lysisbuffer (150 mM NaCl, 5% glycerol, 1% Triton X-100, 1.5 M
MgCl2, 50 mM HEPES, pH 7.5) supplemented with 1 mM
sodium orthovanadate, 2 mM phenylmethylsulphonyl fluo-
ride (PMSF) and protein electrophoresed in SDS-PAGE
Criterion gels (5–20% gradient, Bio-Rad, Gladesville, NSW,
Aust.). Protein expression was detected using the following
antibodies; anti-phosphorylated ERK1/2 (Cell Signaling,
Danvers, MA, USA) and anti-β actin (Sigma-Aldrich) probed
the membrane overnight at 4 °C followed by secondary
antibody incubation at room temperature (RT) for 1 h prior
to visualisation by ECL (GE Health Science, Piscataway, NJ,
USA) and a luminescent image analyser (LAS4000, Fujifilm,
Stamford, CT, USA).
Assessment of immunogenicity of EXnaEFCs
Donor matched EXnaEFCs and HUVECs were isolated (as
above) from a single cord and cultured for one week. As a
positive control donor matched mature dendritic cells (DCs)
were produced as previously described (Rojas-Canales et al.,
2012) with mature DCs (mDCs) confirmed by flow cytometry
utilising antibodies against HLA-DR, CD11c, CD14, CD80, CD83,
CD86 (all BD Biosciences) and CD209 (Miltenyi Biotech).
Donor matched HUVECs, EXnaEFCs, mDCs and unmatched
bone marrow-derived mesenchymal stem cells (MSC, Millipore)
were labelled with mouse anti-human antibodies against MHC
class I (clone FMC16), MHC class II (FMC52) or the isotype
control (X63), all gifts from H Zola (formerly Flinders Medical
Centre, Adelaide, South Australia). Following incubation
(30 min, 4 °C), cells were washed in medium and labelled
with goat anti-mouse Dylight650 secondary antibody (1/100
dilution in medium, Abcam) for 30 min at 4 °C. Cells were
washed, labelled with 7AAD, washed again and then analysed
by FACS.
In selected experiments EXnaEFCs, HUVECs and MSCs
were cultured with 10 ng/ml of human TNF or IFNγ (R&D
Systems) for 48 h prior to antibody labelling and FACS
analysis.
In vitro Matrigel™ tube formation assay
In vitro tube formation of HUVECs and EXnaEFCs was
assessed. HUVECs were stained with 10 μg/ml DiI-Ac-LDL
for 4 h, washed once and incubated overnight under cell
culture conditions. EXnaEFCs were stained with 10 μM
Calcein-AM (eBioscience, San Diego, CA) for 20 min prior to
use. Matrigel™ (10 μl, BD Biosciences) was pipetted into the
wells of an angiogenesis μ-slide (ibidi GmbH, Martinsried,
Germany) and set for 30 min at 37 °C prior to labelled
HUVECs (1 × 104 or 2 × 104 cells per well) without or with
EXnaEFCs (1 × 104 cells per well). Tube formation was
monitored regularly and seven overlapping phase contrast
images were captured (inverted IX70 microscope 4×/0.13NA
objective, an S15 F view camera and Analysis Life Sciences
software (Olympus, Tokyo Japan)) after 6 h of tube
formation. Overlapping images were ‘stitched’ together
using Adobe Photoshop (Adobe Systems, San Jose, CA) and
the number of tubes and branches was quantified manually
on blinded images using ImageJ 1.47 (National Institute of
Health, Bethesda, MD). Fluorescent images were captured
on IX71 microscope (Olympus) with 10×/0.4NA objective and
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Sciences software.
In vivo Matrigel™ plug tube formation assay
CD133+ EXnaEFCs were expanded for 6–8 days prior to 5 × 105
EXnaEFCs being mixed with 500 μl of high concentration
Matrigel™ (BD Biosciences) containing 2 μg/ml basic fibroblast
growth factor (R&D Systems) and 50 units/ml heparin (Sigma-
Aldrich) and injected subcutaneously into one flank of a 6–
8 week old female NOD/SCID mouse. The opposite flank
received a control high concentration Matrigel™ plug contain-
ing no cells. Mice were humanely killed by cervical dislocation
on day 14 post-injection and plugs were removed, washed in
PBS, fixed in 4% paraformaldehyde (VWR International, Radnor,
PA) overnight, embedded in paraffin, cut into 8 μM sections on
amicrotome (RM 2235 Leica, Solms, Germany) and placed onto
slides (Polysine®, Menzel-Gläser, Thermo Scientific). The
sections were investigated for cells expressing CD31 (1:1000,
goat anti-mouse/human CD31, Santa Cruz, Dallas, TX) or
human mitochondria (MTC02, Abcam) using biotinylated rabbit
anti-goat secondary (Abcam) diluted 1:500 with PBS + 3%
normal human serum (NHS, Life Technologies, Carlsbad, CA)
or biotinylated goat anti-mouse secondary (Vector Labs) used
at 1/250 in PBS/3% NHS. Sections were treated with Vectastain
elite ABC regent (Vector Labs, Burlingame, CA) for DAB staining
as per manufacturer's instructions, followed by haematoxylin
and eosin staining. Negative controls included isotype
matched irrelevant antibodies as well as secondary antibody
alone. Images of slides were collected using a Hamamatsu
Nanozoomer slide scanner with CD31+ vessels counted manu-
ally and section areas were quantified using the NDPview
software (Hamamatsu Photonics, Hamamatsu, Japan).
Acute myocardial infarction in CBH-Rnu rats
CBH-Rnu male rats were anaesthetised using isoflurane
(1% in 3–4 l O2/min, Bomac Laboratories, Sydney, Australia)
and mechanically ventilated (tidal volume 3.6 ml, ventilatory
rate 60 breaths/min) (Inspira ASV Ventilator (Harvard Appa-
ratus, Massachusetts, USA)). Once ventilated, rats underwent
a permanent surgical ligation of the left anterior descending
coronary artery to induce acute myocardial infarction (AMI).
Rats then received either 100 μl PBS or 1 × 106 EXnaEFCs
(expanded for 6–8 days) in 100 μl PBS by transepicardial
injection directly below the ligation site before thewoundwas
closed in 3 layers. Rats were allowed to recover on 100%
oxygen and received Carprofen (5 mg/kg) and Norocillin
(10 mg/kg, both Norbrook Laboratories, Melbourne, Australia)
for pain and bacterial management. Control rats did not
undergo surgery. Following a cardiac magnetic resonance
image (MRI) at 7 days post-AMI, blood was collected from tail
veins for serum creatinine detection by a colorimetric test at
SA Pathology (Adelaide, Australia) before humane killing.
Hearts were collected for histology and RNA isolation.
Cardiac magnetic resonance imaging (MRI)
Cardiac MRI was performed on rats using a 1.5 T MR system
(Magnetom Sonata, Siemens, Germany). Cardiac MRI was
performed on rats prior to AMI and one week post-AMI.Animals were placed supine recumbent in the isocentre of
the magnet with a human carotid radiofrequency coil placed
over the thorax. Anaesthesia was maintained by isoflurane.
Two electrocardiography (ECG) electrodes were attached to
the thorax thereby generating a vector ECG. Accordingly, all
MRI images were free breathing, ECG-gated, acquisitions.
Transverse and coronal localiser images were acquired
followed by short axis pilot images, from which a true short
axis stack was prescribed. TrueFISP (Fast Imaging with
Steady-State Precession) cine images (gated to alternate R
waves) were acquired. The stack comprised three contigu-
ous left ventricular slices (each 3 mm thick, with no
intersection gap) providing almost complete coverage of
the left ventricle. The image matrix was 384 × 384, field of
view 185 mm, repetition time 14.72 ms, echo time 1.55 ms,
flip angle 90°, and 20 heart phases were acquired. The
average scan time per animal was 10 min.
MRI image analysis
Left ventricular volumes and derived ejection fraction (EF)
were measured off-line from cine images using commercially
available software (QMASS v7.2, Medis, Netherlands).
Papillary muscles were excluded from calculations. The
end-diastolic (ED) and end-systolic (ES) cine frames were
identified for each slice and the endocardial and epicardial
borders were manually traced. The end-diastolic (EDV) and
end-systolic volumes (ESV) were then calculated using the
true disk summation technique (sum of cavity volumes across
all continuous slices), as previously described (Teo et al.,
2008).
PCR and immunohistochemistry of heart tissue
collected from AMI rats
Quantification of mRNA levels was carried out using qPCR.
Primers designed for rat genes using Primer Blast (National
Institute of Health) and purchased fromGeneWorks (Adelaide,
Australia). Primers were designed to span an intron/exon
border to avoid genomic DNA amplification (Table 1). qPCR
amplification was performed using QuantiTect™ SYBR Green
master mix (Qiagen) on a Rotor-Gene thermocycler (Corbett
Research, Mortlake, Australia) with reaction parameters:
15 min at 95 °C, then cycling of 10 s 95 °C, 20 s 55 °C and
30 s 72 °C; for 45 cycles followed by a melt phase. Data
obtained was analysed using Rotor-Gene Analysis Software
version 6 (Corbett Research). Relative gene expression levels
were calculated by normalising to the rat house-keeping genes
β-actin, CycA, HPRT and YWAHZ using geNorm software
(Vandesompele et al., 2002).
Rat hearts were harvested, fixed in 4% (v/v) buffered
formalin at 4 °C overnight and then embedded in OCT
compound and frozen at −80 °C. Human placenta was
used as a positive control. Tissues sectioned to 5-μm-thick
were stained with anti-human IL3Rβ (CSF2RB: clone 9F5,
3.3 μl/ml (Sun et al., 1996)) or an isotype matched negative
control and biotinylated goat anti-mouse IgG (2 μl/ml,
BD Biosciences) employing VectorStain ABC kit as the
detection system (Vector Laboratories, Burlingame, CA, USA).
Counterstaining was performed using Mayer's haematoxylin
(Dako Agilent Technologies, Glostrup, Denmark). Analysis was
Table 1 Rat primers used in PCR analysis of gene expression
in AMI cardiac tissue.
Rat gene Forward and reverse prime sequence
Tnf F-5′AAAGCATGATCCGAGATGTG3′
R-5′AGCAGGAATGAGAAGAGGCT3′
Sdf1 F-5′CCGATTCTTTGAGAGCCATGT3′
R-5′CAATGCACACTTGTCTGTTGTT3′
Cx3cl1 F-5′GCAGCTTTCCGCTCTGAATA3′
R-5′CTGTTCTGAGCTTCCACCTATC3′
Cd14 F-5′GGAAAGAAACTGAAGCCTTTCTC3′
R-5′AGCAACAAGCCGAGCATAA3′
Ccl2 F-5′GTCTCAGCCAGATGCAGTTAAT3′
R-5′CTGCTGGTGATTCTCTTGTAGTT3′
Mmp9 F-5′CAACCTCACGGACACACA3′,
R-5′CTGCTTCTCTCCCATCATCTG3′
β-actin F-5′CTTCCTTCCTGGGTATGGAATC3′,
R-5′CTGTGTTGGCATAGAGGTCTT3′
CycA F-5′GGCTATAAGGGTTCCTCCTTTC3′
R-5′TTGCCACCAGTGCCATTA3′
HPRT F-5′GACCTCTCGAAGTGTTGGATAC3′
R-5′TCAAATCCCTGAAGTGCTCAT3′
YWAHZ F-5′GACATCTGCAACGACGTACT3′,
R-5′CGGTAGTAGTCACCCTTCATTT3′
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Analysis Life Sciences software (Olympus).
Hematopoietic colony formation assay
UCB isolated CD133+ EXnaEFCs expanded without and with IL3
for 7 days were plated in methylcellulose with a 10× cell
solution (200 μl, IMDM with 2% FCS) mixed with 2 ml of
MethoCult (Stem Cell Technologies) containing erythropoietin
(EPO; 3 U/ml), granulocyte macrophage colony-stimulating
factor (GM-CSF; 20 ng/ml), stem cell factor (SCF; 50 ng/ml)
and interleukin 3 (IL-3, 10 ng/ml). The cell/MethoCult mix
(0.37 ml) was added to 24 well plate wells at 1670 cells/well.
Assays were incubated at 37 °C, 5% CO2 and haematopoietic
colonies were scored after 14 days.
Statistical analysis
Results are generally expressed as mean ± standard error
of the mean (SEM). An unpaired or paired Student T-test, 1-
or 2-way ANOVA for multiple comparisons was performed
to determine statistical significance between groups with
p values b 0.05 considered significant.
Results
Interleukin-3 greatly expands CD133+ non-adherent
endothelial forming cells
CD133+ cells were isolated from umbilical cord blood
via magnetic sorting and cultured in CellGro SCGM media
supplemented with TPO, Flt3L and SCF (complete CellGro
media). Following 6–7 days of culture naEFCs expanded14.6 ± 4.7 fold and by 12–13 days this rose further to
98.6 ± 35.4 fold. To clearly distinguish these expanded cells
from our previously published ‘four day enriched naEFCs’ we
have named the expanded population ‘EXnaEFCs’. Because IL3
and placental growth factor (PlGF) have been shown to have
pro-angiogenic properties (Autiero et al., 2003; Li et al., 2003;
Li et al., 2006), they were also tested here. We used 20 ng/ml
and 25 ng/ml, respectively, as concentrations that saturate
cell surface receptors. As shown in Fig. 1A, the inclusion of IL3
into the medium significantly enhanced EXnaEFC expansion
both at days 6–7 (Fig. 1Ai) and 12–13 (Fig. 1Aii) when
compared to donor matched cells grown in the ‘complete
CellGro’medium alone. Notably, by days 12–13 of culture the
mean fold increase of EXnaEFCs in medium containing IL3 was
~350-fold.
Addition of PlGF did not increase the expansion rate of
EXnaEFCs at either days 6–7 or 12–13 of culture. Further-
more, co-culture of PlGF and IL3 did not increase the
expansion rate beyond that seen with IL3 alone. These data
suggest that the addition of PlGF to the EXnaEFC expansion
media had no effect but identified a specific effect of IL3
(Fig. 1A). Furthermore, cell viability remained high (~90%)
across all groups within 6–7 days of cell culture (Fig. 1Aiii)
and fell slightly thereafter at days 12–13 but did not differ
significantly between groups (Fig. 1Aiv).
To determine if CD133+ EXnaEFCs could be successfully
expanded post-freeze/thaw, EXnaEFCs were expanded in
CellGro medium either directly after isolation from cord
blood or following freezing, liquid nitrogen storage and
thawing. Over the course of 14 days the expansion rates
(Fig. 1Bi) and viability (Fig. 1Bii) of both fresh and frozen
expanded cells were similar.Expansion of EXnaEFCs maintains its pro-vascular
profile in the presence of IL3
We next used flow cytometric analysis to check for possible
variations in EXnaEFC surface profile during expansion. As
shown in Fig. 2, after nine days of cell expansion (without or
with IL3) the EXnaEFCs retained expression of the progenitor
cell markers CD34, CD117 and CD133. Further phenotyping
revealed that VEGFR2 and CD31 were expressed by the
EXnaEFCs, while CD144 and CD146 (both mature EC markers)
were not detectable (Fig. 2). The CD133+ EXnaEFCs revealed
a relatively low but detectable level of CD45 and IL3RA at
the cell surface but not CD38 or CD14. These cells were also
capable of taking up acetylated-low density lipoprotein
(Ac-LDL) and binding U. europaeus lectin (UEA-1) (Fig. 2),
both features of ECs (Timmermans et al., 2009).
Addition of IL3 did not alter the cell surface expression of
any progenitor cell, vascular cell or leukocyte markers
(Fig. 2). Similarly, expression of the IL3RA, uptake of
Ac-LDL and binding of UEA-1 lectin were all unchanged by
the presence of IL3. This suggests that IL3-induced increase
in EXnaEFC numbers is likely due to an expansion of a
homogenous population rather than selective skewing of a
sub-population. Investigation into the cellular mechanisms
underpinning this proliferation suggests that the MAPK
pathway is involved with a significant increase in activated
(ie phosphorylated) ERK1/2 identified in EXnaEFCs with
temporary cell starvation of growth factors (5 h) prior to
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Figure 1 CD133+ naEFCs expansion is enhanced by IL3 and is not affected by freeze/thaw. CD133+ naEFCs isolated from a single
donor were split and cultured under four different conditions; media alone (–), media + PIGF, media + IL3 and media + PIGF + IL3.
(A) Cell proliferation (i and ii) and cell viability (iii and iv) in different growth conditions were assessed after 6–7 days of expansion (i
and iii) and 12–13 days of expansion (ii and iv). Data is shown as mean ± SEM, with proliferation data expressed as the fold change
from the starting number of CD133+ naEFCs normalised to media alone expansion, , n = 5–8, *p b 0.05 versus media alone. (B) To
determine the ability of CD133+ naEFCs to be expanded after being frozen and thawed naEFCs were isolated from cord blood based on
CD133 expression and expanded in media (thick black line) or frozen down in 90% FCS/10% DSMO and placed into liquid nitrogen for at
least one week before thawing and expanding (thin black line). Cell expansion (i) and viability (ii) were recorded for 14 days, graphs
show mean ± SEM, n = 3.
385Rapid and large scale expansion of pro-angiogenic cells with therapeutic potentialIL3 stimulation for 10 min (Fig. 2B). The activation of
ERK1/2 was observed in cells expanded both without and
with IL3.EXnaEFCs exhibit low immunogenicity
As immunological rejection of cells represents a major hurdle
for transplantation, the immunogenicity of CD133-isolated and
EXnaEFCs is of key importance for their use in allogeneic cell
therapy. Hereinwe examinedMHC class I and class II expression
on EXnaEFCs and compared them to donor-matched HUVECs
and mature dendritic cells (mDCs), as well as unmatched
mesenchymal stem cells (MSCs). When data is expressed as afold change in mean fluorescence intensity (MFI) compared
to the isotype control, EXnaEFCs, HUVECs and MSCs all had
very similar levels of MHC class I expression, while the positive
control, mDCs, had significantly higher levels (Fig. 3A).
However, when the MFI fold change of each HUVEC and mDC
line is normalised to its donor-matched EXnaEFCs, HUVECs
express less and mDCs express more MHC class I compared to
EXnaEFCs (Fig. 3C). For MHC class II, data expressed as a fold
change in MFI compared to the isotype control (Fig. 3B) shows
EXnaEFCs expressing higher levels of class II than both HUVECs
and MSCs, but significantly less than the mDCs. Similarly, when
the MFI fold change of HUVECs and mDCs is normalised to its
donor-matched EXnaEFCs, HUVECs express less, while mDCs
express more, MHC class II compared to EXnaEFCs (Fig. 3D).
CD45
VEGFR2
CD14
CD144
CD38
CD146
CD117
IL3RA
CD34 CD133
UEA-Lectin Ac-LDL
CD31
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
Co
un
t
102 103 104 105 106
0
25
50
75
100
B
A
actin
pERK
- IL3 - IL3    kDa
no IL3 + IL3
50
50
- IL3 - IL3
0
5
10
15 no  IL3 + IL3
*
*
Figure 2 IL3 supports a vascular profile for expanded CD133+ naEFCs and activates ERK1/2. (A), CD133+ isolated naEFCs were
expanded in CellGro media with IL3 (dashed grey line) or without IL3 (solid black line). Solid grey peak represents negative control.
Cells were labelled with fluorescently tagged antibodies targeting hempoietic progenitor, endothelial, leukocyte and monocyte cell
marker. The ability of cells to take up DiI-Ac-LDL and FITC-labelled UEA-1 lectin were also assessed by flow cytometry. Representative
donor cell line on day 9 of expansion, n = 4. (B), EXnaEFCs expanded without or with IL3 for 10 days prior to growth factor starvation
(5 h) then without or with IL3 stimulation for 10 min. Cell lysates blotted for phosphorylated ERK1/2 or β actin loading control
(left panel). Quantified data expressed as mean band intensity ± sem, n = 4, *p b 0.05 versus untreated (right panel).
386 L.M. Moldenhauer et al.As de novo expression of MHC I and MHC II occurs in
response to TNF and IFNγ, respectively (Collins et al., 1986;
Pober et al., 1983), we next examined induction of MHC
molecules on EXnaEFCs, HUVECs and MSCs in response to
these pro-inflammatory cytokines. Each cell type cultured
with cytokine for 48 h was normalised to untreated controls.As shown in Fig. 3E, MHC class I was significantly increased in
EXnaEFCs exposed to TNF and there was a trend towards an
increase in response to IFNγ. HUVECs also increased MHC
class I in response to TNF and IFNγ. To note, the extent of
the increase appeared less in EXnaEFCs when compared to
HUVECs. Cytokines did not alter the expression of MHC class I
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Figure 3 EXnaEFCs exhibit low immunogenicity. Donor matched EXnaEFCs, HUVECs and mDCs were isolated from umbilical cords.
After 7 days in culture cells were labelled with antibodies against MHC class I (A,C,E), MHC class II (B,D,F) or isotype control. (A,B) The
fold change in mean fluorescence intensity (MFI) compared to the isotype control was calculated for each cell type from each donor,
in addition non-donor matched MSCs were used as a comparator cell. Each triangle represents one data point, the line represents the
mean. (C,D) The expression of MHC on each HUVEC and mDC was normalised to the donor matched EXnaEFCs, n = 4–9. (E,F) Donor
matched EXnaEFCs and HUVECs and unmatched MSCs were cultured with 10 ng/ml of TNF (grey bars) or IFNγ (black bars) for 48 h
prior to antibody labelling, the change in MHC expression was normalised to the respective cell type grown in the absence of cytokine
(no treatment (NT), white bars), n = 3–6. Bar histograms show mean ± SEM. *p b 0.05 versus naEFC (A–D) or NT cells (E–F).
387Rapid and large scale expansion of pro-angiogenic cells with therapeutic potentialon MSCs (Fig. 3E). As shown in Fig. 3F, TNF failed to increase
the expression of MHC II on all cells tested and IFNγ
marginally increased MHC II expression on EXnaEFCs only.EXnaEFCs are pro-angiogenic
A key feature of mature ECs and some progenitor cells, such
as ECFCs, is their ability to form tube-like structures on
Matrigel™ in vitro. We first investigated the ability of
EXnaEFCs alone to form tube-like structures on Matrigel™;
these cells retained their round appearance and did not
form any tube-like structures over a 12 h time course,irrespective of IL3 exposure (data not shown). To further
investigate the pro-angiogenic potential of these cells we
cultured 1 × 104 EXnaEFCs with an equivalent number of
HUVECs (ie 1 × 104 cells). Control wells contained HUVECs
alone either at 1 × 104 or 2 × 104 cells/well. Each donor
HUVEC line was performed in triplicate, with tube structures
and branching points (branches) counted manually at 6 h and
normalised to 2 × 104 HUVECs.
We observed that wells containing 1 × 104 HUVECs
formed fewer tubes and branch points than wells containing
2 × 104 HUVECs. Wells containing co-cultures of 1 × 104
HUVECs and 1 × 104 EXnaEFCs (expanded without or with
IL3) formed the same number of tubes and branch points as
388 L.M. Moldenhauer et al.the wells containing 2 × 104 HUVECs and significantly more
tubes and branch points than the wells containing 1 × 104
HUVECs alone (Fig. 4A). This suggests that the EXnaEFCs are
pro-angiogeneic via their contribution to tube structure
formation in vitro. Notably, tube structure formation was
maintained by EXnaEFCs expanded with IL3 (Fig. 4A).
To investigate the physical association between the
EXnaEFCs and HUVECs in the aforementioned experiments
we labelled the EXnaEFCs with Calcein-AM labelled and the
HUVECs with DiI-Ac-LDL labelled and undertook immunoflu-
orescence microscopy. As shown in Fig. 4B the EXnaEFCs
(green) are not randomly scattered throughout the well, but
are in close proximity to the HUVEC (red) tubes.
Previously we have shown that the day four enriched
naEFCs are unable to form tube structures by themselves in
vitro, but do form lumenised vessels in vivo (Appleby et al.,1x
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Figure 4 EXnaEFCs contribute to tube formation in vitro. To deter
tube formation, mature HUVECs were cultured in vitro on Matrigel
absence of IL3. (A) The number of tubes and branches was quanti
donors. Data expressed as mean ± SEM with *p b 0.05 versus 2 × 104 H
6 h in culture, with HUVECs labelled with DiI-Ac-LDL (red) and EXnaEF
images are shown.2012). Thus, we next tested the ability of EXnaEFCs to
contribute to vessel formation in vivo by injecting Matrigel™
plugs containing EXnaEFCs (and control plugs containing no
cells) into each flank of NOD/SCID mice. Plugs were removed
14 days following insertion, paraffin embedded, sectioned
and stained with anti-mouse/human CD31 or MTC02, a
human specific mitochondrial antibody. As shown in Figs.
5A and B, the CD31+ EXnaEFCs are clearly visible only within
the plug in which they were seeded. Notably, while we were
unable to observe EXnaEFCs forming CD31+ vessels contain-
ing erythrocytes within these sections, the EXnaEFCs did
cluster together within the Matrigel™ and confirmed to be of
human origin as they bound MTC02, an antibody targeting
the human mitochondria (Fig. 5C). Further investigation
of these plugs revealed that the surrounding connective
tissue contained CD31+ vascular structures which contained1x104 HUVEC1x10
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389Rapid and large scale expansion of pro-angiogenic cells with therapeutic potentialerythrocytes (Fig. 5E) with serial sections confirming CD31
expressing vessels when compared to the negative isotype
control (Fig. 5D). Utilising the human-specific mitochondrial+ PBS: CD31/H&E
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Figure 5 EXnaEFCs are pro-angiogenic in vivo. Matrigel™ plugs con
NOD/SCID mouse and removed after 13 days. Paraffin embedded plu
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(indicated by the dashed line) with the CD31 (iso) negative control an
erythrocyte contained CD31+ vessels, (F) human mitochondria staining
CD31+ staining of vessels in tissue surrounding the plug. c = stain posit
(H) The number of CD31+ vessels in the tissue surrounding the Matrigel™
versus PBS.antibody (MTC02) we identified that these CD31+ vascular
structures were not of human origin (Figs. F–G). Of more
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390 L.M. Moldenhauer et al.EXnaEFCs demonstrated a significant increase in the number
of CD31+ vasculature structures in the surrounding tissue
compared to the controls (Fig. 5H).
Expanded naEFCs ameliorate acute myocardial
infarction in rats
To investigate the therapeutic potential of human EXnaEFCs,
CBH-Rnu male rats were used in a model of acute myocardial
infarction (AMI) as their immunodeficiency provides toler-
ance to xenografted cells. Briefly, rats underwent a surgical
ligation of the left anterior descending coronary artery to
induce myocardial infarction prior to receiving either PBS or
EXnaEFCs injected transepicardially below the ligation site.
Rats were analysed by cardiac MRI pre-surgery and seven
days post-surgery to measure changes in the left ventricular
mass (LVM) and ejection fraction (EF). Blood was also
collected to determine levels of serum creatinine as well
as the hearts for gene expression and histology.
We first assessed the presence of transplanted human
cells in host myocardium by immunochemistry. As human IL3
was used to expand the cells and this growth factor (and its
receptor) has very low homology between human and mouse
and thus reagents are not cross-reactive (Hayashida et al.,
1990) we used an anti-human IL3Rβc antibody to specifically
identify the human EXnaEFCs in the transplanted areas in
the rats. Fig. 6A shows in AMI rats treated with PBS alone
that neither an isotype control IgG (Fig. 6A, top left panel)
nor the anti-IL-3Rβc (Fig. 6A, top middle panel) could detect
human cells. In contrast, in AMI rats + EXnaEFCs IL3Rβc
expressing cells were identifiable at the site of injection
(Fig. 6A, bottom left panel). To note, in the same rat heart,
but distal to the EXnaEFC injection site no IL3Rβc expressing
cells were detectable (Fig. 6A, bottom middle panel).
Human placental tissue was used as a positive control
(Fig. 6A, right top and bottom panels). Interestingly, while
we did not observe the integration of human EXnaEFCs into
the vasculature of the myocardium, the expression pattern
of these cells in the rat heart was strikingly similar to that
observed in the human placental tissue and suggestive of a
pro-angiogenic cell exuding its effects via a paracrine
function (Fig. 6A, enlarged images).
Fig. 6B shows that compared to the pre-AMI group, rats
administered PBS or EXnaEFCs exhibited a significant
reduction in ejection fraction. However, the cell therapy
group exhibited a 5% improvement of ejection fraction when
compared to the PBS alone group. Delivery of EXnaEFCs did
not improve LVM (data not shown). Creatine phosphate
in the muscle is broken down into creatinine that enters
the blood stream. While this is a constant process within
the body, high levels of serum creatinine are linked to
cardiovascular distress. AMI significantly increased serum
creatinine levels in rats treated with PBS. Strikingly
however, delivery of EXnaEFCs returned creatinine to similar
levels to pre-AMI rats (Fig. 6B).
Expanded naEFCs promote gene expression for
repair of AMI
Cardiac tissue was collected and qPCR was utilised to measure
endogenous rat mRNA of known AMI affected genes; Tnf, Sdf1,Cd14, Cx3cl1, Ccl2 and Mmp9. Expression was normalised
to housekeeper genes (β-actin, CycA, Hprt and Ywahz) and
control rats which had not undergone surgery. As shown in
Fig. 7, administration of EXnaEFCs rescued the hearts from
AMI-induced (i) suppression of Tnf, Sdf1 and Cd14 and
(ii) increase expression of Cx3cl1. To note, the cell therapy
group exhibited increased gene expression of ccl2 and Mmp9
when compared to both control rats and those treated with
PBS immediately post-AMI (Fig. 7).
Multipotency of EXnaEFCs
Asahara recently demonstrated that a single HUCB derived
CD133+ cell could give rise to cells of either the hematopoi-
etic or endothelial lineage (Masuda et al., 2011). Using a
similar methylcellulose hematopoietic colony formation
assay we executed a fate analysis of EXnaEFCs expanded
without or with IL3. As shown in Table 2, when the EXnaEFCs
were cultured with GM-CSF, SCF, IL3 and EPO for 14 days a
variety of cell types were detected including early progen-
itors of both erythrocyte and myeloid lineages (CFU-GEMM),
the erythrocyte lineage (BFU-E), the granulocyte/monocyte
progenitor lineages CFU-GM, CFU-G and CFU-M. Also shown
in Table 2, a comparison of naEFCs expanded without and
with IL3 which suggests a similarity between these cells with
respect to the number and type of colonies formed.
Discussion
The ability to repair and generate blood vessels is critical
to improve outcomes in a number of diseases including
cardiovascular disease and diabetes. Endothelial progenitor
cells contribute to blood vessel formation and vascular
repair in animal models of ischemia (reviewed in (Timmermans
et al., 2009; Yoder, 2012)) but human trials have yielded
moderate success (Lipinski et al., 2007; Martin-Rendon et al.,
2008).
Human EPCs have been isolated by a variety of means
that essentially fall into two broad categories, 1) cell culture
conditions to enrich for EPC colonies (Hill et al., 2003; Ito et
al., 1999; Kalka et al., 2000) and 2) the isolation of cells
based on surface marker expression e.g. CD34 or CD133
(Appleby et al., 2012; Bompais et al., 2004). These methods
warrant refining as they (i) lack the specificity of EPC
selection and (ii) are commercially prohibitive based on
high cell culture costs and requiring ~5 weeks of culture to
reach an ECFC number sufficient for therapeutic application
(Gulati et al., 2003; Hur et al., 2004). Herein we have
isolated CD133+ naEFCs from cord blood and expanded
the population ~350-fold in less than two weeks, using
serum-free medium. Given that 1–3 × 106 CD133+ naEFCs
can be isolated from ~60 ml cord blood, this protocol can
produce in excess of 5 × 108 cells within 14 days. Serum-free
expansion of CD133+ umbilical cord blood cells has
previously been achieved using medium supplemented with
SCF (100 ng/ml), TPO (20 ng/ml), Flt3L (100 ng/ml), IL3
(20 ng/ml), plus VEGF and IL6 (Masuda et al., 2012). Here,
using significantly lower concentrations of SCF (40 ng/ml),
TPO (10 ng/ml) and Flt3L (40 ng/ml), together with IL3
(20 ng/ml), we were able to achieve similar expansion in the
same time period. Our investigation into cell viability also
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Figure 6 EXnaEFCs are localised near the heart vasculature and reduce cardiac damage in rats following AMI. Rats given surgically-
induced AMI received either PBS or 1 × 106 EXnaEFCs via injections into the infarct site. (A), Seven days post-surgery, hearts from
AMI + PBS and AMI + EXnaEFCs were examined for human cells via immunohistochemistry using a human specific anti-IL3Rβ antibody
versus isotype control (iso ctl). Left and right panels of AMI + EXnaEFC staining represent regions of the heart in close proximity or distal
to the site of cell injection, respectively. Human placenta (far right panels) served as controls for human IL3Rβ expression. Images shown
represent one of four experiments. Prior to retrieval of the hearts, the ejection fraction was assessed by MRI (B) and peripheral blood was
taken tomeasure serum creatinine (C). Control rats which did not undergo any surgery also had MRI and creatinine data collected. Data is
shown as the mean ± SEM, n = 3–6. *p b 0.05 versus controls, #p b 0.05 EXnaEFCs versus PBS.
391Rapid and large scale expansion of pro-angiogenic cells with therapeutic potentialsuggests that the IL3-induced expansion of the naEFCs was
not merely via pro-survival effect as the rate of cell viability
was similar across all media combinations assessed. We were
also able to show that isolated CD133+ EXnaEFCs could be
frozen, thawed and expanded equally well as the freshly
isolated cells, an advantage for the use of these cells as a
potential allogeneic cell therapy.
The expression of CD133 by EXnaEFCs differentiates them
significantly from the well characterised ECFCs which are
CD133− and suggests that the EXnaEFCs are a more primitive
circulating EPC rather than the EC-like ECFCs. EXnaEFCs also
express CD117, CD31, and low levels of CD45, but do not
express CD14, CD38, CD144 or CD146. The expression of CD45
is a contentious issue in this field but increasing evidence
supports that cells expressing this marker are clinically
relevant. For example, Asahara's recent development of a
clonogenic assay for cells with endothelial potential showedthat these cells clearly expressed CD45 (Masuda et al., 2011). A
study by Estes et al. showed aCD34+CD133+CD45lowCD31+CD14−
population capable of promoting tumour blood vasculature in
mice (Estes et al., 2010). Furthermore, reduced frequency of
circulating CD34+VEGFR2+CD45low and CD34+CD133+CD45low
cells correlates with peripheral and coronary artery disease,
while CD34+VEGFR2+CD45− shows no such correlation (Estes et
al., 2010; Schmidt-Lucke et al., 2010). Our data demonstrate
that co-culture of EXnaEFCs with HUVECs in Matrigel™ in vitro
promoted tube-like structure formation. Fluorescence micros-
copy suggested that expanded naEFCs were in close proximity
to and possibly incorporated into HUVEC structures.
The infusion of a heterogeneous population of progenitor
cells, either from bone marrow or peripheral blood into
myocardial infarction patients has been shown to improve
left ventricle ejection fraction, end-systolic and diastolic
volumes and increase coronary blood flow of the affected
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Figure 7 EXnaEFCs control gene expression in cardiac tissue following AMI. Rats given surgically-induced AMI received either PBS
(grey bars) or 1 × 106 EXnaEFCs (black bars) via injections into the infarct site. Seven days post-surgery cardiac tissue from the infarct
site was collected, RNA isolated and rat gene expression was analysed by real time PCR. Control heart tissue was collected from rats
which had not undergone any procedure (white bars, Ctl). Gene expression was normalised to housekeepers. Data is shown as the
mean ± SEM, fold changed compared to the control rats, n = 3–6, *p b 0.05 versus controls, #p b 0.05 EXnaEFCs versus PBS.
392 L.M. Moldenhauer et al.vessel (Assmus et al., 2002; Jiang et al., 2010; Schachinger
et al., 2004; Strauer et al., 2002). As delivery of human EPCs
into the infarct site of rats with surgically induced AMI has
shown increased cardiac function as measured by ejection
fraction (Hong et al., 2013), fraction shortening (Schuh et
al., 2008) and left ventricle end systolic and diastolic
pressure (Hu et al., 2009) we executed similar experiments
to examine the restorative effect of the human EXnaEFCs.
Intracardial injection of 1 × 106 EXnaEFCs immediately
following AMI demonstrated a decrease in serum creatinine
levels when compared to AMI rats administered PBS alone.
Notably, the creatinine levels measured in the untreated
control CBH/Rnu rats were below published values for
immunocompetent rats such as Sprague Dawley which we
have previously used in a similar model of AMI (Palm and
Lundblad, 2005; Richardson et al., 2013). As measurement of
serum creatinine is an indirect determinant of cardiac
damage that rises acutely post-myocardial infarction,
measurements within the first two to three days would
better represent cardiac damage. This will be examined inTable 2 Hematopoietic properties of EXnaEFCs. Human naEFCs expa
growth factors GM-CSF, IL3, SCF and EPO for 14 days prior to colony c
morphology. EXnaEFCs formed blast-forming unit-erythroid (BFU-E),
methylcellulose. (mean ± sem, n = 3).
BFU-E CFU-GEMM
EXnaEFC no IL3 85 ± 35 11 ± 1
EXnaEFC + IL3 138 ± 43 15 ± 4future studies. Furthermore, the CBH/Rnu rats in this
study were routinely ~80–150 g, half the weight of Sprague
Dawley rats which weigh ≥250 g each at the same age (Hong
et al., 2013; Schuh et al., 2008). A higher level of
AMI-induced mortality was observed in the CBH/Rnu rats
and the ejection fraction in our rats was significantly lower
than documented elsewhere, both prior to surgery (63%
compared to 82%) and post-surgery (20% compared to 39%)
(Hong et al., 2013). While we demonstrate a modest 5%
increase in EF seven days following administration of
EXnaEFCs versus PBS controls, it must be noted that a
recent meta-analysis from 2625 patients showed that
compared to the standard treatment, bone marrow cell
transplantation delivered intracoronary exhibited a 3.96%
improvement in EF and correlated with a significant decrease
in all-cause mortality in these patients (Jeevanantham et al.,
2012). Based on these observations, the contribution of
EXnaEFCs to alleviate ischemic injury warrants further
investigation. Improved cardiac performance in animalmodels
has been shown four-weeks post-EPC transfer (Hong et al.,ndedwithout or with IL3 for 7 days were seeded in MethoCult plus
ounting and staining with May Grunwald/Giemsa to assess cellular
colony-forming units (CFU)-GEMM, -GM, -G and -M colonies in
CFU-GM CFU-G CFU-M
24 ± 11 42 ± 6 9 ± 1
10 ± 2 40 ± 10 11 ± 1
393Rapid and large scale expansion of pro-angiogenic cells with therapeutic potential2013; Hu et al., 2009; Masuda et al., 2012; Schuh et al., 2008),
suggesting a longer time period within our study may well have
improved outcomes even further. In addition, our in vitro work
suggested that the EXnaEFCs expressed less MHC classes I and II
when compared to donor matched mature DCs, and were less
receptive to TNF and IFNγ for increased surface expression of
MHC class I. Our in vivo experiments utilised immunocompro-
mised rodents and thus conclusive evidence of ‘low immunoge-
nicity’ will require immunocompetent animals, longer in vivo
studies and would also benefit from a comparison to MSCs. This
is part of an ongoing study within our laboratory.
To determine a profile of gene activation within the hearts
of AMI rats following EXnaEFC administration, we performed a
comprehensive PCR analysis of cardiac tissue seven days
post-infarct and treatment. We reveal that the rats receiving
EXnaEFCs exhibited rescued gene expression of Tnf, Sdf1 and
Cd14. TNFα has been implicated in stimulating fibroblast
proliferation and assisting in heart repair post-AMI (Jacobs et
al., 1999). SDF1 supports further EPC mobilisation from the
bone marrow (Jin et al., 2006) and CD14 expressing macro-
phages may aid in the clearance of necrotic tissue (Ertl and
Frantz, 2005). Rats administered expanded naEFCs also
exhibited levels of Cx3cl1 closer to those found in control
rats. Herein Ccl2 gene expression was highest in rats receiving
EXnaEFCs. Notably, the CCL2 receptor, CCR2, is expressed by
EPCs and vascular smooth muscle cells and is associated with
angiogenesis (Schober, 2008). Mmp9, which was significantly
increased in rats administered EXnaEFCs, has been shown to
liberate EPCs from the bone marrow (Heissig et al., 2002; Liu
and Velazquez, 2008). Together this data suggest that
EXnaEFCs trigger the production of a suite of rat-derived
pro-angiogenic factors, many of which also mediate the
clearance of damaged and necrotic tissue.
While immunocompromised animals, (such as the T lympho-
cyte deficient CBH/Rnu rats used here), are commonly
employed to mimic human AMI (Dick et al., 1997; Masuda et
al., 2012; Shultz et al., 1995), studies indicate that immuno-
suppression prevents leukocyte recruitment into cardiac tissue
post-AMI, reduces the clearance of dead cells and significantly
delays recovery time (Kloner et al., 1978). Therefore the
suitability of immunocompromised animals in AMI experiments
generally is questionable and conclusions must be made
prudently. Finally, if we are to consider allogeneic cells for
therapeutic application understanding their immunogenicity is
important.We show that EXnaEFCs express slightly higher levels
of MHC class I and class II when compared to donor-matched
ECs. However, when stimulated with the pro-inflammatory
cytokines TNF or IFNγ, two cytokines routinely present at a
transplant site (Ono et al., 1998), the increase in MHC I
expression on EXnaEFCswasmodest compared to the ECs.While
more reactive than the MSCs, the EXnaEFCs were significantly
lower in MHC expression when compared to the mDCs.
Herein we have described the isolation, serum-free expan-
sion and characterisation of a non-adherent population of
human endothelial progenitor cells (EXnaEFCs). These cells
express progenitor cell and EC markers and display
pro-angiogenic properties that can assist EC tube formation in
vitro and in vivo. Interleukin-3 significantly enhanced EXnaEFC
expansion and these cells demonstrated a clinically relevant
improvement of heart function seven days post-AMI with
reduced serum creatinine levels and an increase in
pro-angiogenic genes in the rat heart. The mechanismsunderpinning the effect of IL3 on EXnaEFCs are yet to be fully
elucidated, however data to support its use come from it
enhancing CD34+ and proangiogenic cell survival (D'Atri et al.,
2011; Zeoli et al., 2008) as well as EC migration and tube
formation in vitro (Dentelli et al., 1999). Our work contributes
to this by demonstrating an increase in ERK activation in
response to IL3. With studies showing that high-dose interven-
tion of stem cells within two weeks is most effective in AMI
(Dimmeler et al., 2008; Richardson et al., 2013), our rapid
expansion of EXnaEFCs to clinically relevant numbers within a
therapeutically advantageous window supports the further
investigation of IL3 in cell therapy.
Importantly, in our study, the EXnaEFCs did not form
capillary-like tubes on their own in vivo and therefore do not
merit the ‘endothelial’ status (Hirschi et al., 2008; Yoder,
2012). A broader pro-angiogenic phenotype is noted instead.
Taken together, these expanded human cells differ significantly
from those we originally characterised and phenotyped as
naEFCs with CD133+ isolation from cord blood and enrichment
for four days in defined media (Appleby et al., 2012). These
results show IL3 as a potent growth factor for human CD133+
cell expansion with clear pro-angiogenic properties, in vitro
and in vivo.
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